Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Model-guided design of a stabilized pre-fusion class III viral fusogen, rabies virus glycoprotein

Project description

Towards improved rabies vaccines

Many antiviral vaccines are designed to target surface glycoproteins that mediate fusion and entry into the host cell. The EU-funded FUSEDESIGN project is focussing on the development of a rabies vaccine based on the rabies virus glycoprotein (RVG). Researchers will employ a structure-guided approach to design mutations to stabilise the RVG pre-fusion protein using a homology model of the protein. Lead candidates will be characterised and used in vivo to immunise mice. Results have the capacity to improve existing rabies vaccines and may also lead to the design of vaccines against other viruses such as herpesviruses.

Objective

This proposal aims to stabilize the pre-fusion form of rabies virus glycoprotein (RVG), the most structurally-tractable clinically-relevant class III fusogen by combining computational biology, immunology, and structural biology.
Rabies virus is fatal; it kills 55,000 people each year and costs billions to control it in animals. Current human rabies vaccines are cumbersome to use and prohibitively costly, thus there is demand for a new generation of rabies vaccines.
Enveloped viruses’ fusion glycoproteins are important subunit vaccine candidates. Structure-guided stabilization of class I fusogens has been a major advance in vaccinology. Many major human pathogens have class III fusogens (notably, all herpesviruses and rabies virus): several post-fusion structures have been reported, but their antigenically critical pre-fusion forms have not been stabilized.
A high-quality homology model of RVG will guide design of mutations to stabilise the trimeric pre-fusion protein. Designed mutants will be transiently expressed in mammalian cells, selected for stability, and characterized immunologically. Lead candidates will be used as immunogens in mouse models and in structural studies. These data will guide design of improved rabies vaccines, and provide insights into RVG’s interaction with neutralizing antibodies and host receptors. Certain structural elements are conserved across class III fusogens, and so the approach may lead towards stabilization of herpesvirus fusogens.
The fellowship will be based between two departments at a world-class host institution. Together, they will offer the Researcher an unusual combination of exposure to both cutting-edge molecular biochemistry and Europe’s leading academic centre for translational vaccine development. This unique training will equip the Researcher with a truly discipline-spanning skill set and position her to make a leading contribution to the development of novel antiviral interventions and public health.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2018

See all projects funded under this call

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Net EU contribution
€ 224 933,76
Address
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
United Kingdom
Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 224 933,76